PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer

PARIS, FRANCE, June 23, 2022 – PathoQuest, a leading Contract Research Organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies, today announced that Michael Mellor-Clark has been appointed Chief Commercial Officer (CCO).

“We are very pleased to welcome Michael Mellor-Clark as CCO to PathoQuest. Michael is bringing 20 years of leadership experience in sales management to the field of biosafety services to the biotech industry. Michael will successfully lead and grow our sales and marketing organization to reach our ambitious objectives.” This is great timing as the cell and gene therapy industry is lifting off and we are opening our new  US site in Wayne (PA) to be closer to our US-based customers” said Jean-François Brepson, PathoQuest CEO.

Michael Mellor-Clark has more than 20 years of commercial experience in biosafety testing services. After gaining experience as an Account Manager and then Global Key Account Manager, Michael progressed into several leadership roles. He has successfully led Account Management teams in Asia Pacific, Europe, and North America. He has also established high-performing Commercial Strategy, Key Account Management, and Internal Sales Teams.

“I am very excited to be part of the PathoQuest team,” said Michael Mellor-Clark. “The biologics industry is adopting NGS-based assays for virus detection and genetic characterization because (compared to older methods) they are quicker, more robust, and ethical. PathoQuest is the global leader in this field.”

About PathoQuest

PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D, and GMP grades to ensure the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. It enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases. PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.